急性缺血性脑卒中三种常用神经保护药物成本-效果分析

摘要

目的:评价依达拉奉、神经节苷脂和马来酸桂哌齐特治疗急性缺血性脑卒中的成本效果.方法:效果为NIHSS量表测得的有效率,通过对已有研究进行网络Meta分析的间接治疗比较来获得;成本指直接医疗成本,其来源参考<中国急性缺血性脑卒中诊治指南2010>和市场价格.结果:采用常用剂量治疗14天时,依达拉奉、神经节苷脂和马来酸桂哌齐特组的有效率分别为97.15%、91.15%和81.64%,成本分别为7 276元、9 516元和3 636元.结论:与神经节苷脂相比,依达拉奉具有绝对的成本效果优势.%Objective: To estimate cost-effectiveness of Edaravone, Ganglioside and Cinepazide Maleate for Acute Ischemic Stroke. Methods: The outcome was NIHSS effectiveness rate, which was abtained through Indirect Treatment Comparison. Direct medical cost was based on marketing prices and the "China Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke (2010)" . Results: Within 14 days and with the given dosage, clinical effectiveness rate was 97.15%, 91.15% and 81.64%, while costs were 7 276, 9 516 and 3 636 yuan for Edaravone, Ganglioside and Cinepazide Maleate group, respectively. Conclusion: For Acute Ischemic Stroke, Edaravone was dominant with Ganglioside.